Inmed Pharmaceuticals Inc (INM) Stock Price, Quote & News

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 604 669 7207

Fax: 778 945 6800

Website: www.inmedpharma.com

Address:

885 West Georgia Street, Suite 1445, Vancouver, Canada

letsgopeeps Apr. 29 at 1:48 PM

$INM Its a loooong moment

0 · Reply

focafoca99 Apr. 28 at 5:42 AM

$INM amended previously issued preferred investment options with Sabby and certain H.C. Wainwright affiliates.

0 · Reply

FlyingTargets Apr. 27 at 9:38 PM

$MARA $HTCO $ENVB $INM FOF

0 · Reply

newsfile_corp Apr. 27 at 9:31 PM

https://nfne.ws/294412 $INM @inmedpharma #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

0 · Reply

Space0 Apr. 23 at 12:27 AM

$INM good news?

0 · Reply

FillSniper42 Apr. 22 at 10:19 PM

IQST is bottomed out with an upcoming product launch and severely undervalued.. - No dilution - $300M+ yearly revenue with 1B+ forecasted for 2027 - $18 Price Target by litchfield (currently trading under $2) $BYND $AKAN $HCWC $SBEV $INM WW

0 · Reply

Holdlong78 Apr. 15 at 3:36 PM

$INM any moment will explode

0 · Reply

Space0 Apr. 15 at 12:25 PM

$INM two weeks without any update or even a single tweet !

0 · Reply

focafoca99 Mar. 31 at 1:42 AM

$INM is now back in the usual Nasdaq clock, with a minimum-bid notice and 180 days to get the stock back above $1.

0 · Reply

newsfile_corp Mar. 27 at 9:05 PM

https://nfne.ws/290289 $INM @inmedpharma #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

0 · Reply

InMed Pharmaceuticals Amends Preferred Investment Options

Mar 27, 2026, 5:04 PM EDT - 4 weeks ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Mar 23, 2026, 7:30 AM EDT - 5 weeks ago

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Mar 18, 2026, 1:45 PM EDT - 5 weeks ago

InMed Pharmaceuticals Transcript: Sidoti March Small-Cap Virtual Conference

Mar 9, 2026, 7:30 AM EDT - 7 weeks ago

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Mar 6, 2026, 5:04 PM EST - 7 weeks ago

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Feb 11, 2026, 5:23 PM EST - 2 months ago

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Dec 17, 2025, 8:00 PM EST - 4 months ago

InMed Announces Results of 2025 Annual General and Special Meeting

Dec 12, 2025, 5:31 PM EST - 4 months ago

InMed Provides Update on BayMedica Commercial Business

Dec 11, 2025, 2:00 PM EST - 4 months ago

InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025

Nov 18, 2025, 7:30 AM EST - 5 months ago

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 6, 2025, 4:51 PM EST - 6 months ago

InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Oct 16, 2025, 8:30 AM EDT - 6 months ago

Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 9, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

ZYME

Sep 23, 2025, 8:30 AM EDT - 7 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 18, 2025, 2:00 PM EDT - 7 months ago

InMed Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025

Sep 16, 2025, 1:39 PM EDT - 8 months ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 5, 2025, 1:33 PM EDT - 8 months ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 PM EDT - 8 months ago

InMed Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Jul 28, 2025, 7:00 AM EDT - 9 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jun 27, 2025, 7:00 AM EDT - 10 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 11 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 24, 2025, 7:00 AM EDT - 11 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 13, 2025, 4:30 PM EDT - 11 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

May 12, 2025, 6:00 PM EDT - 1 year ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 1 year ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 3, 2025, 7:30 AM EST - 1 year ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Jan 22, 2025, 7:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 21, 2025, 7:30 AM EST - 1 year ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Dec 18, 2024, 8:00 PM EST - 1 year ago

InMed Announces Results of 2024 Annual General Meeting

Dec 17, 2024, 4:56 PM EST - 1 year ago

InMed Enters Into Standby Equity Purchase Agreement

Nov 19, 2024, 7:30 AM EST - 1 year ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 14, 2024, 4:45 PM EST - 1 year ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 12, 2024, 2:00 PM EST - 1 year ago

InMed Pharmaceuticals Transcript: Status Update

Nov 8, 2024, 4:44 PM EST - 1 year ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 5, 2024, 8:30 AM EST - 1 year ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jun 13, 2024, 1:45 PM EDT - 2 years ago

InMed Pharmaceuticals Transcript: Emerging Growth Conference 72

Jun 10, 2024, 5:18 PM EDT - 2 years ago

InMed to Present at the Emerging Growth Conference

May 14, 2024, 8:30 AM EDT - 2 years ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

Apr 18, 2024, 8:00 AM EDT - 2 years ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 16, 2024, 8:00 AM EDT - 2 years ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 4, 2024, 8:00 AM EDT - 2 years ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Mar 20, 2024, 8:30 AM EDT - 2 years ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Feb 13, 2024, 5:41 PM EST - 2 years ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 9, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Jan 18, 2024, 4:41 PM EST - 2 years ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 16, 2024, 8:00 AM EST - 2 years ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Sep 23, 2022, 1:00 PM EDT - 3 years ago

InMed Pharmaceuticals Earnings Call Transcript: Q4 2022

Feb 15, 2022, 3:08 AM EST - 4 years ago

InMed Pharmaceuticals Earnings Call Transcript: Q2 2022

Sep 23, 2021, 8:00 PM EDT - 4 years ago

InMed Pharmaceuticals Earnings Call Transcript: Q4 2021

letsgopeeps Apr. 29 at 1:48 PM

$INM Its a loooong moment

0 · Reply

focafoca99 Apr. 28 at 5:42 AM

$INM amended previously issued preferred investment options with Sabby and certain H.C. Wainwright affiliates.

0 · Reply

FlyingTargets Apr. 27 at 9:38 PM

$MARA $HTCO $ENVB $INM FOF

0 · Reply

newsfile_corp Apr. 27 at 9:31 PM

https://nfne.ws/294412 $INM @inmedpharma #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

0 · Reply

Space0 Apr. 23 at 12:27 AM

$INM good news?

0 · Reply

FillSniper42 Apr. 22 at 10:19 PM

0 · Reply

Holdlong78 Apr. 15 at 3:36 PM

$INM any moment will explode

0 · Reply

Space0 Apr. 15 at 12:25 PM

$INM two weeks without any update or even a single tweet !

0 · Reply

focafoca99 Mar. 31 at 1:42 AM

$INM is now back in the usual Nasdaq clock, with a minimum-bid notice and 180 days to get the stock back above $1.

0 · Reply

newsfile_corp Mar. 27 at 9:05 PM

https://nfne.ws/290289 $INM @inmedpharma #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing

0 · Reply

BadBankofGotham Mar. 25 at 3:48 PM

$INM Who´s selling here.....

2 · Reply

OfficialStocktwitsUser Mar. 24 at 10:41 PM

$INM RSI: 28.67, MACD: -0.0469 Vol: 0.06, MA20: 0.84, MA50: 0.94 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BadBankofGotham Mar. 24 at 6:38 PM

$INM Hmm sell on good News why...

1 · Reply

Space0 Mar. 23 at 9:51 PM

$INM good news and the stock drops more than 11%? What if the news was bad? This doesn't make sense

0 · Reply

AlwaysLearning72 Mar. 23 at 3:06 PM

$INM it looks like shares available to short went from 150K to 0... Shorts will need to cover eventually

0 · Reply

BadBankofGotham Mar. 23 at 2:05 PM

$INM Sell on good News...what the Heck..lol...

0 · Reply

BadBankofGotham Mar. 23 at 12:33 PM

$INM Yes let´s go

0 · Reply

aw20 Mar. 23 at 12:19 PM

$INM expecting this to retest 1 this week. If we have a clear break of 1, then the real party can start 👀

0 · Reply

aw20 Mar. 23 at 11:56 AM

$INM sold at 0.95 again reloaded at 0.75. Let's rererun it back until we squeeze 👀

0 · Reply

vvvvvvrebel89130 Mar. 23 at 11:54 AM

$INM filed shelf in front of news; sill sell into it

0 · Reply

TA_Kongen Mar. 23 at 11:46 AM

$INM I have a feeling they will uno reverse this and pump it today.

0 · Reply

Market Cap	2.56M
Revenue (ttm)	4.94M
Net Income (ttm)	-8.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-165.18%
Debt to Equity Ratio	0.00

Volume	13,034
Avg Vol	116,376
Day's Range	N/A - N/A
Shares Out	3.31M
Stochastic %K	21%
Beta	0.52
Analysts	Strong Buy
Price Target	$45.00